STUDY QUESTION: Does the hypermethylation of the maelstrom spermatogenic transposon silencer (MAEL) promoter and subsequent de-repression of transposable elements represent one of the causes of spermatogenic failure in infertile men?
Introduction
Clinically, determining the causes of non-obstructive azoospermia (NOA) can be a diagnostic dilemma. NOA can be further subclassified as hypospermatogenesis (HS), early or late maturation arrest, Sertoli cell-only syndrome and tubular sclerosis based on histopathological diagnosis. HS is the most frequent finding in patients with NOA among different studies (Haddad et al., 2004; Abdullah and Bondagji, 2011; Madbouly et al., 2012) , and it is believed that the causes of HS are complex and multifactorial. We previously showed that HS accounted for 43% of all patients with NOA and the underlying causes were identified in 45% of patients and idiopathic in 55% (Cheng et al., 2017) . For decades, accumulating evidence shows that aberrant expressions of certain sterility-related genes may be linked to HS; however, studies of single gene mutation/polymorphism, deletion and copy number variation seldom provide a full explanation. Epigenetic regulation can silence gene expression without any change in the DNA sequence and may provide an alternative etiology for HS. To explore this idea further, we used a whole genome DNA methylation array and microarray mRNA expression analysis to identify the reproduction-related genes that are hyper-methylated in their promoter region and under-expressed in the HS testes. Our results uncovered that maelstrom spermatogenic transposon silencer (MAEL), was the most significant candidate gene whose aberrant methylation in the promoter region might be involved in the pathophysiology of HS (Cheng et al., 2017) . We identified a specific promoter region from −131 to +177 relative to the transcription start site (TSS) in which the hypermethylation of CpGs is proposed to associate with deficient expression.
MAEL, first discovered in the fly ovary, is a component of perinuclear nuage found in the germ line cells (Findley et al., 2003 , Costa et al., 2006 , Soper et al., 2008 . The nuage associated proteins have been shown to be involved in the repression of transposable elements (TEs) in flies, zebrafish and mice (Lim and Kai, 2007; Klattenhoff and Theurkauf, 2008) . Mouse MAEL was found to interact with Mili and Miwi and participate in Piwi interacting RNA (piRNA) mediated TEs silencing pathway (Costa et al., 2006) . In B6 mice, MAEL protein was exclusively expressed in the spermatocytes and round and elongated spermatids (Costa et al., 2006 , Soper et al., 2008 , and Mael mutants (Mael B6−/− ) revealed reduction of pachytene piRNA levels, derepression of LINE-1 (L1), excessive DNA damage, abnormal chromosomal synapsis and meiotic failure (Costa et al., 2006) . In mice with different genetic background, Mael mutants (Mael 129−/− ) showed additional defects in acrosome and flagellum formation in round spermatids (Castaneda et al., 2014) . These results suggest that MAEL is required for mammalian meiosis and post-meiotic spermiogenesis. Human MAEL RNA has been shown to localize to the spermatocytes and spermatids of adult testis, and MAEL is also expressed in various cancer cell lines. The promoter activity of human MAEL could be influenced by DNA methyltransferase inhibitor, suggesting that the expression of MAEL might be regulated by DNA methylation (Xiao et al., 2010) . Although a deficiency of MAEL leads to the activation of TEs and spermatogenic failure, and MAEL expression may be affected by methylation dysregulation, there is no direct evidence to link these findings. Moreover, MAEL is crucial for spermatogenesis; however, there is only limited data showing the role of human MAEL in the testicular development during the mini-puberty period (Hadziselimovic et al., 2011) . We hypothesized that the repression of TEs by MAEL is evolutionarily conserved in humans and de-repression of TEs by hypermethylation of MAEL may be a cause of spermatogenic failure in infertile men. This study set out to clarify the relationships between promoter DNA methylation of MAEL and the expression of MAEL and L1 in a targeted DNA methylation (TDM) model and to determine the methylation levels of MAEL gene in men with HS versus normal spermatogenesis (NS) to explore the associations of MAEL methylation with clinical features.
Materials and Methods

Promoter construct
The construct, pCpGL-MAEL, containing the MAEL promoter and part of the gene body (spanning from −188 to +294) was generated by PCR amplification using PrimeSTAR GXL DNA polymerase (Takara Bio Inc., Otsu, Japan). The primer sequences for cloning were: forward, 5′-cgAAGCTTATGTTCCTCAACACTTTTCACA-3′ and reverse, 5′-gaTTCGAATCCTGCACGAAGAAATAGTAAG-3′. The purified PCR fragments were subcloned into CpG free pCpGL-basic luciferase reporter vector (gift from M. Rehli's laboratory, Regensburg, Germany). DNA insertion was confirmed by DNA sequencing and the vector was transformed into the PIR1 strain of Escherichia coli (Invitrogen, Carlsbad, CA).
In vitro DNA methylation and luciferase assay
The methylated plasmid (me-pCpGL-MAEL) was generated by adding 160 μM S-adenosylmethionine and 2.5 U/μg of M.SssI, HhaI or HpaII (New England Biolabs Inc., MA) in reaction buffer into 20 μg of plasmid DNA according to the manufacturer's instructions. Plasmid DNA was phenol/chloroform extracted, ethanol precipitated and quantified using a Nanodrop spectrophotometer (Thermo Fisher Scientific, Loughborough, UK). Methylation-sensitive restriction enzymes HhaI and HpaII and methylation insensitive MspI were used to confirm the complete methylation. The me-pCpGL-MAEL or mock (unmethylated-pCpGL-MAEL) were transfected into human NCI-H358 cells (American Type Culture Collection, Manassas, VA) by using Lipofectamine TM 3000 (Invitrogen). Transfection with CpG free pCpGL-basic was used as negative control and pCpGL-cytomegalovirus (CMV) (M. Rehli's laboratory) served as positive control. After 24 h, luciferase and Renilla activity were measured by dual luciferase substrate system (Promega, Madison, WI). The relative luciferase activity was normalized by calculating the ratio of firefly/Renilla values.
The reporter gene system for targeted MAEL promoter
The reporter gene system for targeted MAEL promoter consisted of two constructs. The first construct was built by fusion of pCpG-MAEL and pcDNA TM 6/TR (Invitrogen). The second construct, pTetO-enhanced green fluorescent protein (EGFP), consisted of CMV, Tet repressor binding sequence and EGFP reporter. These two constructs were co-transfected into NCI-H358 cells.
In vitro DNA methylation, transfection and EGFP expression
Four microgram PCR-amplified MAEL promoter DNA were incubated with 20 U of M.SssI in the presence of 160 μM S-adenosylmethionine to induce in vitro methylation. Then the methylated MAEL promoter DNA (1 μg) was denatured at 95°C and transfected into NCI-H358 cells (1 × 10 5 cells) three times at Days 1, 3 and 5, using DMRIE-C (Invitrogen)
according to the manufacturer's instructions. Fluorescence intensity of EGFP in more than 300 cells was measured using the ImageJ software (NIH). Transfection of unmethylated MAEL promoter DNA was used as negative control, and transfection of unmethylated MAEL promoter DNA plus Doxycycline (1 μg/ml) was used as positive control.
5-Aza-dc-20-deoxycytidine treatment
The methylated MAEL promoter DNA transfected NCI-H358 cells were treated with 15 μM of 5-aza-dc-20-deoxycytidine (5-Aza) for 5 consecutive days, then the EGFP intensity was measured.
RNA isolation and quantitative real-time RT-PCR
Total RNA (1 μg) was isolated from the transfected cells and quantitative real-time RT-PCR (qRT-PCR) was used to measure the MAEL and L1 transcript levels, as previously described (Cheng et al., 2006) . The primer sequences were as following: MAEL, forward, 5′-AGAAATGGCTCGAG AATGGA-3′ and reverse, 5′-GTTGTGGAGGCTGTTGGTTT-3′; L1, forward, 5′-GAGACTAGGAAGAAACTGCATCAAC-3′ and reverse, 5′-CC TTTTATTTTGAGCCTATGTGTGT-3′.
Immunofluorescence
Cells were fixed in 2% (w/v) formaldehyde and blocked with 10% (v/v) goat serum, then the slides were incubated with Anti-Mael antibody (1:300; Abcam, Cambridge, UK) or 3531-hORF1-N-terminal antibody (1:300; gift from Professor John V. Moran) in 0.1% (w/v) saponin followed by phosphate buffer saline (PBS) washes. The cells were incubated with Fluorophore-conjugated secondary antibodies (Goat Anti-Rabbit IgG H&L) in 0.1% saponin. After PBS washes, the slides were mounted in mounting medium containing 4′,6-diamidino-2-phenylindole (DAPI) (Thermo Fisher Scientific).
Patients and clinical workup
Twenty-six patients with histopathologically proven NOA and HS and 12 patients with obstructive azoospermia and normal spermatogenesis (NS) were enrolled in this study. This study was approved by the Institutional Review Board of the National Cheng Kung University Hospital, Tainan, Taiwan (A-ER-102-432), and written informed consent was obtained from all participants. HS is defined as all stages of spermatogenesis being present, but the number of germ cells being reduced to a varying degree. All patients received a detailed history taking, physical examination, hormonal profile testing, chromosome karyotype and Y chromosome microdeletion analysis. History of testicular insults included heat exposure, varicocele, genitourinary tract infection, undescended testis and trauma. Testicular volume was measure by Seager orchidometer. Serum levels of FSH, LH, total testosterone (T) and prolactin (PRL) were obtained using radioimmunoassay kits (Siemens Healthcare Diagnostics, Tarrytown, NY). Chromosome analysis was done using GTG banding (G-bands by trypsin using Giemsa), and the Y-chromosome microdeletion test was done using a combination of gene-based and sequence-tagged sites (STS)-based primers (Teng et al., 2002) .
Testicular samples and spermatogenic score
All patients received diagnostic testicular biopsy and/or testicular sperm retrieval and agreed to provide a small piece of testicular tissue,~5 mm in diameter, for further study. One-third of the tissue volume was sent for histopathologic diagnosis and at least 100 cross-sections of seminiferous tubule were independently and blindly reviewed by two specialists. The severity of HS was determined by a spermatogenic scoring system with slight modification (Puhse et al., 2011 , Cheng et al., 2017 . Briefly, the percentage of all tubules with elongated spermatids was calculated. The spermatogenic score represents the [number of tubules containing elongated spermatids] ÷ [total number of tubules evaluated] × 10. In this study, the HS patients were subdivided into three groups based on the spermatogenic score: ≥8 = mild HS; ≥4 to <8 = moderate HS; <4 = severe HS.
DNA extraction and methylation analysis of MAEL promoter DNA (10 μg) was purified by using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA) and bisulfite conversion was performed by using the Qiagen Epitect Bisulfite Kit (Qiagen) according to the manufacturer's instructions. Because the DNA methylation patterns are different between germ cells and somatic cells, the composition of the cells will affect the methylation level measurement. Therefore, the result obtained using total DNA extraction represents a reading not of programmatic change but of the relative composition of each starting tissue. To diminish the impact of different cell compositions in a testicular sample, isolation of enriched population of germ cells from testicular tissue was performed prior to DNA extraction, which was conducted based on rigorous enzymatic digestion, elutriation and ultracentrifugation . Methylation status of the MAEL promoter region was assessed by using PyroMark CpG Assay (Qiagen). Primers were designed by using Methprimer program (http:// www.urogene.org/methprimer), and the primer sequences contain at least one CpG site at 3′ end to maximally discriminate methylated and unmethylated DNA. Pyrogram was quantified by using PyroMark Q24 Software version 2.0.6 (Qiagen). The degree of methylation at each CpG was determined by percentage methylation, and the mean percent methylation of each CpG was used to compare the difference between the HS and NS groups.
qRT-PCR
qRT-PCR was used to measure the mRNA transcript levels of MAEL and L1 from germ cell-enriched testicular cells as described above.
Statistical analysis
Data were analyzed with Prism 6 (GraphPad Software, San Diego, CA). Continuous variables are presented as the mean ± standard error (SE) or median with an interquartile range. Differences between variables within two groups were analyzed using Student's t-test, Mann-Whitney U test or χ 2 test. The differences among more than two groups were tested using one-way ANOVA or Kruskal-Wallis test. The relationships between variables were analyzed by regression and correlation analysis. Significance was set at P < 0.05.
Results
Identification of regulatory region of MAEL gene
To identify the DNA methylation-mediated regulatory region of MAEL gene, CpG island (CGI) searcher program (http://www.urogene.org/ cgi-bin/methprimer/methprimer.cgi) was used to predict the CGI in the MAEL promoter region. The result showed that one CGI is observed from position −158 to +404 relative to TSS (Fig. 1A) . In addition, our previous high-throughput analysis revealed that the region from −131 to +177 is a putative methylation-mediated regulatory region in human testis (Cheng et al., 2017) . To verify the impact of regional methylation on expression, a pCpGL-MAEL (from −188 to +294) luciferase reporter vector was generated. Then, the pCpGL-MAEL was treated with various methyltransferases. HhaI recognizes 5′-GCG^C-3′ site; HpaII recognizes 5′-C^CGG-3′; and M. SssI methylates all CpGs (Fig. 1B) . These vectors were transfected into human NCI-H358 cells, and our results showed that transfection with pCpGL-MAEL resulted in significant increase in luciferase expression, compared to transfection with pCpGL-basic (P < 0.0001; Fig. 1C ).
Additions of restriction enzymes HhaI, HhaI plus HpaII, and M. SssI resulted in progressive decreases in luciferase expressions, compared to unmethylated controls (P = 0.0097, P = 0.0001, P < 0.0001, respectively; Fig. 1C ). The luciferase activity showed a decreasing trend in accordance with increasing methylated CpG sites (P < 0.0001).
Targeted DNA methylation of MAEL promoter suppresses promoter activity
To validate the effect of DNA methylation on gene expression, we established a targeted DNA methylation (TDM) reporter system according to previous publications (Hsiao et al., 2010 , Teng et al., 2011 . A systematic diagram of this system is shown in Fig. 2A . Briefly, this EGFP reporter system consists of two constructs. One plasmid, which expresses Tet repressor (TetR), is controlled by the MAEL promoter (from −188 to +294). Another plasmid, which expresses EGFP, contains CMV and two tetracycline operators (TetO2). These two constructs were co-transfected into NCI-H358 cells. Expression of TetR governed by MAEL promoter leads to the binding of TetR to TetO2 and the repression of EGFP. Methylation of MAEL promoter suppresses the expression of TetR, which in turn results in the de-repression of EGFP. Our results showed that cells carrying this TDM reporter system originally presented with very low level of EGFP and transfection of methylated MAEL DNAs subsequently resulted in an increase in fluorescence intensity of EGFP (P = 0.0078, Fig. 2B and C). In this TDM system, addition of doxycycline (Dox) which inhibits the bindings of TetR to TetO2 was used as positive control. To validate the de-repression of EGFP was due to TDM at the MAEL promoter, the NCI-H358 cells were treated with demethylating agent 5-Aza to reverse the de-repression of EGFP. Our result showed that 5-Aza significantly decreased the expression of EGFP (P = 0.0293; Fig. 2B and C) , suggesting the partial restoration of TetR expression.
Targeted DNA methylation of MAEL promoter suppresses MAEL expression and increases L1 expression in vitro
Cells transfected with methylated DNA induce the endogenous DNMT-mediated methylation within the targeted region and silence the gene expression after cellular passages (Hermann et al., 2004a,b) . We then further tested the effects of TDM on the expressions of MAEL and L1 genes. Our results showed that both mRNA and protein levels of MAEL were significantly decreased (P = 0.0013 and P < The luciferase reporter construct (pCpGL-MAEL, from −188 to +294) containing the array predicted region (from −131 to +177) was generated, and the vectors were treated with different methyltransferases, including M.SssI, HhaI and HpaII. (C) The methylated and unmethylated vectors were transfected into NCI-H358 cells for 24 h. Firefly luminescence was normalized to Renilla luminescence and reported as relative luciferase activity. All experiments were done in triplicate and independently performed at least three times. Statistical significance is indicated by asterisks (**P = 0.0097; ***P = 0.0001; ****P < 0.0001).
0.0001, respectively; Fig. 3A -C) and the mRNA and protein levels of L1 were significantly increased in TDM cells (P = 0.0080 and P < 0.0001, respectively; Fig. 3D-F ), compared to non-TDM cells.
Differential methylation patterns of the MAEL gene in patients with HS versus NS
To investigate the DNA methylation status of MAEL promoter in infertile men, DNA purified from germ cell-enriched testicular cells was obtained from 26 patients with HS and 12 patients with NS. A total of 26 CpG sites are noted in the region from −131 to +177 (Fig. 4A) . The profiles of methylation status in this region after pyrosequencing analysis are shown in Fig. 4B . The mean methylation percentage of the each CpG in the MAEL promoter was significantly higher in patients with HS versus NS (P < 0.01 for each position).
The associations of MAEL methylation level with gene expression and testicular phenotype
To study the relationship between MAEL methylation level and gene expression, we first measured the transcript levels of the MAEL gene in 26 HS and 12 NS patients. Significantly lower transcript levels were noted in patients with HS versus patients with NS (P = 0.0131; Fig. 5A ). The correlation between mean MAEL methylation levels and transcript levels in our patients revealed that MAEL methylation levels was inversely related to the transcript levels (P = 0.001; r 2 = 0.220; Fig. 5B ). We then subdivided our patients into four groups based on spermatogenic score and compared the methylation levels among the groups. Twelve patients with the spermatogenic score of 10 were categorized as NS; eight patients with scores of 8-9 were the 'mild' HS group; 12 patients with scores of 4-7 were the 'moderate' HS group; and six patients with scores of 1-3 were the 'severe' HS group. Sub-dividing our patients according to the severity of spermatogenic failure revealed a progressive increase in the MAEL methylation levels (P = 0.0022; Fig. 5C ). Patients with moderate and severe HS had significantly higher methylation levels than patients with NS (P = 0.0316 and 0.0036, respectively). Given that MAEL can represses L1 expression, we further tested the transcript levels of L1 in our patients. The results showed that L1 transcript levels were significantly higher in patients with HS versus patients with NS (P = 0.0303; Fig. 4D ).
Comparing the clinical features of patients based on methylation levels
Twenty-six patients with HS were subdivided into two groups based on the median value of methylation levels, and their clinical features were compared (Table I) . Patients with high methylation levels had significantly higher FSH levels (P = 0.045), lower total testosterone levels (P = 0.006), smaller testicular sizes (P = 0.023 for right; P = 0.015 for left) and lower spermatogenic score (P = 0.027). However, there were no significant differences in age distribution, the frequency of previous or current testicular insults, serum luteinizing hormone level, serum prolactin level, karyotype abnormality, Y chromosome microdeletions or overall genetic anomalies between the two groups.
Discussion
Our previous high-throughput analysis has suggested that hypermethylation of the MAEL promoter maybe associated with NOA and HS. In this study, we confirm the importance of a specific MAEL promoter region (from −131 to +177) in which increased methylation is sufficient to cause repression of MAEL and de-repression of L1. This region consists of 26 CpGs and is localized within the CGI. Given that TDM method can methylate a specific locus, our results suggest that induction of endogenous DNA methylation of these 26 CpGs is crucial for TEs control. In addition, the targeted methylation-induced gene silencing was partially reversed by addition of 5-Aza, confirming that the MAEL promoter can be regulated by DNA methylation. Our results from human cells are consistent with prior reports demonstrating that transcriptional de-repression of L1 was remarkably increased in the adult testis of Mael null mice (O'Donnell et al., 2008) . Overexpression of peri-nuclear and nuclear L1 has been shown to induce double stand DNA breaks, synaptic defects, genome instability and meiotic failure (Soper et al., 2008) . In this work, MAEL promoter hypermethylation and higher L1 transcript levels were noted in patients with HS, implying that aberrant methylation of MAEL promoter might be associated with spermatogenic failure via de- Figure 3 Effects of targeted DNA methylation of MAEL on the mRNA and protein expressions of MAEL and Line-1 (L1). The NCI-H358 cells were transfected with me-pCpGL-MAEL (2 μg) or pCpGL-MAEL (2 μg) for 3 days. The transcript levels were measured by qRT-PCR, and the protein levels were measured by immunofluorescence staining (A) The MAEL transcript levels were significantly decreased in targeted DNA methylation (TDM) cells (**P = 0.0013). (B and C) The immunostaining intensities of MAEL were significantly decreased in TDM cells (****P < 0.0001). C is the quantification of intensity levels of B.
(D) The L1 transcript levels were significantly increased in TDM cells (**P = 0.0080). (E and F) The immunostaining intensities of L1 were significantly increased in TDM cells (****P < 0.0001). F is the quantification of intensity levels of E. Scale bar = 20 μm. repression of L1. However, we did not provide direct evidence, at the molecular level, for the link between elevated L1 activity and testicular failure in humans. Detection of DNA breaks in TDM system and testicular germ cells will be done in our future studies. In this study, NOA patients with HS had significantly higher methylation levels of the MAEL gene compared to patients with NS. The methylation levels were inversely correlated with MAEL expressional levels and positively correlated with the severity of spermatogenic failure. Additionally, the low MAEL expression was commensurate with the elevated L1 transcript levels in patients with HS. Thus, our data from human testes is consistent with the in vitro TDM study and the findings from Mael null mice (Soper et al., 2008) . Although, MAEL is known as a transposon silencing gene and is essential for spermatogenesis, mutation or polymorphism of the MAEL gene in infertile men has never been reported so far. To date, only one report showed the association between impaired expression of MAEL gene and boys with cryptorchidism (Hadziselimovic et al., 2011) . Our results for the first time suggest that methylation dysregulation of the MAEL gene may contribute to one of the causes of spermatogenic failure in infertile men.
There is increasing evidence that DNA methylation status may be altered by sex, age, environmental exposures, pharmacologic agents and dietary components of parents (Bollati et al., 2009 , Ng et al., 2010 , Madrigano et al., 2011 . In this study, we compared the clinical features between patients with high and low methylation levels of the MAEL promoter. There was no significant difference in age distribution between the two groups. Moreover, the frequency of prior or current testicular insults, including varicocele, heat exposure, genitourinary tract infection/inflammation, undescended testis and testicular trauma, were non-significantly different, as was difference in genetic anomaly. Therefore, we cannot currently identify certain exposures associated with changes of DNA methylation in this study. Further epidemiologic studies examining the associations of particulate matter, chemical agents and nutrient deficiency with changes in DNA methylation is needed. On the other hand, patients with high methylation levels of MAEL revealed smaller testicular sizes, higher FSH levels and lower total testosterone levels than patients with low methylation levels. We believe that these differences arise as a consequence of defective spermatogenesis. Because MAEL is expressed in spermatocytes and spermatids, it is reasonable to speculate that hypermethylation of MAEL and subsequent de-repression on transposable elements during pubertal development may be associated with affected proliferation of germ cells and impaired spermatogenesis in adult.
In patients with HS, the consistently elevated methylation levels of the 26 CpGs was found despite the various clinical features, suggesting that the measurement of the methylation level may be feasible to predict the severity of spermatogenic failure or the outcome of testicular sperm retrieval. In recent years, the DNA methylation biomarker has rapidly evolved into broader clinical applications, such as molecular stratification, disease diagnosis, therapy prediction and outcome monitoring (Levenson, 2010; Mikeska and Craig, 2014) . However, the research of the methylation dysregulation in male infertility faces the daunting challenge of obtaining testicular tissue for analysis, and only a handful of studies reported the methylation changes of testis-expressed genes in patients with NOA (Ferfouri et al., 2013 , Ramasamy et al., 2014 . Until recently, the use of cell-free DNA from seminal fluid showed promising result to be an alternative to testicular tissue for the evaluation of methylation status (Wu et al., 2013) . It has been demonstrated that testis-specific methylated promoters in cell free DNA can represent the methylation status of testicular DNA. The methylation percentage measured in cell-free seminal DNA was correlated with paired testicular cell DNA (Wu et al., 2016) . Therefore, we believe that a cost-effective and non-invasive seminal fluid-based MAEL DNA methylation assay may serve to clinical use in the near future.
Spermatogenesis is a highly ordered process and relies heavily on the regulation of epigenetic modification. Here we show that targeted methylation of specific MAEL promoter region leads to repression of MAEL and de-repression of L1 in human cells. Patients with hypermethylation of the MAEL gene were found to have more severe spermatogenic failure, and this aberrant methylation is independent from acquired testicular insults or known genetic anomaly. The relationship between MAEL hypermethylation and spermatogenic failure described above is a crucial transposon control mechanism known to be evolutionarily conserved from flies to humans. Because NCI-H358 cells are human somatic cells and do not express piRNAs and piRNA pathway proteins, further studies regarding the MAEL-associated protein and RNAs in TDM cells could serve to advance our understanding the biochemical function of MAEL in human spermatogenesis. Undescended testis (n (%)) 1 (7.7) 1 (7.7) 1
Testicular trauma (n (%)) 1 (7.7) 0 (0) 1
Seminal tract infection (n (%)) 0 (0) 1 (7.7) 1
Testicular volume (ml)
Right side 17.1 ± 0.6 7.3 ± 2.3 0.023
Left side 16.7 ± 1.4 6.7 ± 2.3 0.015
Hormonal profile
Follicle stimulating hormone (FSH) (mIU/ml) 5.8 ± 0.9 22.2 ± 5.8 0.045
Luteinizing hormone (LH) (mIU/ml) 4.2 ± 0.8 7.5 ± 2.4 0.400
Total testosterone (T) (ng/ml) 4.5 ± 0.7 2.2 ± 0.4 0.006
Prolactin (PRL) (ng/ml) 8.4 ± 1.3 9.8 ± 4.1 0.193
Overall genetic anomaly (n (%)) 1 (7.7) 1 (7.7) 1 47, XXY (n (%)) 0 (0) 1 (7.7) 1
AZFc deletion (n (%)) 1 (7.7) 0 (0) 1 Spermatogenic score 6.4 ± 0.8 3.9 ± 0.8 0.027
